About We Trust Study

What is the WE TRUST study

The WE-TRUST Study is a multi-center randomized clinical trial to assess the impact of a ‘Direct to Angio Suite’ (DTAS) workflow on stroke patient outcomes.

In the DTAS workflow stroke patients are diagnosed and treated in the interventional suite without interruption.Triage imaging is usually performed in the CT/MR suite after which the patient is sent to the interventional suite for treatment. In DTAS approach/workflow the Cone-Beam CT (CBCT) capabilities of the interventional X-ray system are utilized to perform triage, directly followed by stroke treatment. The study will be running in 16 sites to enroll 500+ patients globally.

Primary objective:
To demonstrate that the DTAS triage workflow involving CBCT results in superior patient outcome (90 day mRS) in ischemic stroke patients with confirmed Large Vessel Occlusion as compared to the conventional CT/MR triage workflow.

Why was this study performed?

Outcomes for stroke patients are closely tied to how fast they receive treatment: Every 30 minutes delay before treatment reduces the chance of a good outcome by 14%*, and every hour of delay ages the brain by 3.6 years compared to a normally aging brain*.

Currently, when a possible stroke patient arrives at the Emergency Department, typically first a CT or MRI exam is acquired for stroke triage. In case of an ischemic stroke the patient is then treated in an interventional suite. Several studies have indicated that a Direct to Angio Suite (DTAS) workflow can reduce the time to treatment and improve patient outcomes. The WE-TRUST (Workflow optimization to rEduce Time to endovascular ReperfUsion in Stroke Treatment) study aims to provide the most comprehensive assessment to-date that the DTAS triage workflow involving CBCT results in faster treatment and thereby improved patient outcome.

[*] ahajournals.org/doi/10.1161/STROKEAHA.118.021989

[*] ncbi.nlm.nih.gov/pubmed/16339467

Protocol

A short summary of the protocol and link to download the PDF.

Download protocol (Pdf) (33.0KB)

Participants

Milestones

Publication of rationale and design of the study

FPI (first patient in)

Interim analysis at 75% of patients treated

Publication of study results

Presentation of WE-TRUST study by Dr Nogueira and Dr Ribó at SLICE online 2020

First site to start with the study

Interim analysis at 50%

LPI (last patient in)

Milestones

Presentation of WE-TRUST study by Dr Nogueira and Dr Ribó at SLICE online 2020

Publication of rationale and design of the study

First site to start with the study

FPI (first patient in)

Interim analysis at 50%

Interim analysis at 75% of patients treated

LPI (last patient in)

Publication of study results

In the media

How tech is transforming stroke patients treatment

Learn more about the latest innovations in diagnosing and treating strokes.
Learn more

We-Trust study announced

We-Trust study assesses whether it is possible to diagnose, plan and treat stroke patients without requiring an initial CT or MRI exam.
Learn more

Funding & support

Philips proudly sponsors and supports this global multi-center study, which is facilitated by current state-of-the-art CBCT capabilities of the Philips’ Neuro Interventional Suite to enable time-efficient triage of acute stroke patient with great confidence.

Would you like to know more about the Philips vision on the Direct To Angio Suite approach and product solutions? Check the Philips DTAS page.

Workflow Optimization to Reduce Time to Endovascular

Reperfusion for Ultra-fast Stroke Treatment

What is the WE TRUST study

The WE-TRUST Study is a multi-center randomized clinical trial to assess the impact of a ‘Direct to Angio Suite’ (DTAS) workflow on stroke patient outcomes.